Pledge/Unpledge

Thyrocare's promoter, Dr. Arokiaswamy Velumani, restructured an existing pledge on Feb 25, 2022. This involved a simultaneous creation and release of encumbrance on 1.35 million shares (2.54% of total share capital) with Edelweiss ARC, for security against an inter-corporate deposit by a promoter group company.

For investors, the key takeaway is that these transactions caused no *net change* in the overall percentage of promoter shares pledged.

Currently, 9.74% of Dr. Velumani's total holding remains pledged, amounting to 2.54% of Thyrocare's total shares.